文献速递甲状腺疾病

甲状腺乳头状癌中MEK1基因激活突变的特征分析

Characterization of Activating Mutations of the MEK1 Gene in Papillary Thyroid Carcinomas.
PubMed 文献 · Thyroid · 2019-01-01

本研究在101例缺乏其他已知驱动突变的甲状腺乳头状癌(PTC)中检测MEK1突变,发现2例(2%)携带MEK1第3外显子框内缺失,另在常规分子检测中识别1例类似突变。MEK1阳性肿瘤均呈包膜内生长且以滤泡结构为主,表达谱呈RAS样并伴高甲状腺分化评分,Western blot证实MAPK通路激活。

要点

  • MEK1激活突变见于约2%无其他驱动突变的PTC,均为第3外显子框内缺失。
  • MEK1阳性PTC呈包膜内生长、以滤泡结构为主,表达谱为RAS样且分化评分高。
  • MEK1突变是PTC中MAPK通路激活的另一机制,可解释部分驱动突变阴性病例。

核心结论

  • 本研究报道PTC中存在功能性MEK1突变,均为第3外显子框内缺失,代表MAPK通路激活的另一机制。
  • MEK1阳性PTC以滤泡生长模式为主,表达谱呈RAS样且甲状腺分化评分高。

研究设计与样本

  • 研究分析了101例缺乏其他已知驱动突变的PTC,采用Sanger测序和靶向下一代测序检测MEK1突变状态。
  • 另研究64例滤泡癌和Hürthle细胞癌及32例滤泡腺瘤,并用另一系列甲状腺肿瘤的靶向测序评估MEK1突变。
  • 对选定肿瘤进行了Western blot和RNA-seq分析。

主要发现

  • 在2/101(2%)无其他已知遗传改变的PTC中检出MEK1突变,在0/64滤泡癌和Hürthle细胞癌及0/32滤泡腺瘤中未检出。
  • 两个阳性肿瘤携带相同框内缺失p.L98_I103del;K104I(c.292_309del18;c.311A>T),位于基因第3外显子。
  • 常规分子肿瘤分析另发现1例MEK1框内缺失p.I99_K104del(c.294_311del18),也位于第3外显子。
  • Western blot分析显示其中1例肿瘤存在MAPK通路激活。
  • RNA-seq分析显示这些肿瘤为RAS样并具有高甲状腺分化评分。

临床怎么用

  • 对缺乏BRAF、RAS等已知驱动突变的PTC,可考虑检测MEK1第3外显子框内缺失以明确MAPK通路激活机制。
  • MEK1阳性PTC多表现为包膜内滤泡型生长,随访病例术后无病生存,但需更多数据验证预后意义。

局限性

  • MEK1突变阳性病例数少(共3例),随访仅2例,预后关联证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Genetic alterations activating the mitogen-activated protein kinase (MAPK) signaling pathway, most commonly BRAF and RAS mutations, are common in papillary thyroid carcinoma (PTC). Somatic mutations of the MEK gene, also known as mitogen-activated protein kinase kinase 1 (MAP2K1), coding for a signaling protein downstream of BRAF, have been found in several cancer types. The goal of this study was to investigate if functional MEK1 mutations occur in thyroid cancer (TC). Methods: We analyzed MEK1 mutation status in a series of 101 PTCs lacking other known driver mutations using Sanger sequencing and targeted next-generation sequencing. In addition, 64 follicular and Hürthle cell carcinomas and 32 follicular adenomas were studied. The occurrence of MEK1 mutations was evaluated using another series of thyroid tumors studied by targeted next-generation sequencing. Western blot and RNA-seq analyses were performed on selected tumors. Results: We detected MEK1 mutations in 2/101 (2%) PTCs that otherwise had no known genetic alterations, in 0/64 follicular and Hürthle cell carcinomas, and in 0/32 follicular adenomas. Two positive tumors carried the same in-frame deletion p.L98_I103del; K104I (c.292_309del18; c.311A>T) located in exon 3 of the gene. One additional MEK1 mutation was identified following routine molecular tumor profiling. The tumor had an in-frame deletion p.I99_K104del (c.294_311del18) also located in exon 3. Western blot analysis of one of the tumors showed activation of the MAPK pathway. Using RNA-seq analysis to evaluate changes in gene expression, these tumors were RAS-like and showed a high thyroid differentiation score. Phenotypically, the MEK1-positive PTCs were all encapsulated and had a predominantly or exclusively follicular architecture, being diagnosed as a classic papillary type with a significant follicular pattern ( × 2) or follicular variant PTC ( × 1). Follow-up was available for 2 patients, with no evidence of disease found 2 and 10 years postsurgery. Conclusions: In this study, we report the occurrence of functional MEK1 mutations in PTC. All mutations are in-frame deletions in exon 3 of MEK1, representing another mechanism of activation of the MAPK pathway in papillary carcinomas with a predominantly follicular growth pattern.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Borrelli N, Panebianco F, Condello V, et al. Characterization of Activating Mutations of the MEK1 Gene in Papillary Thyroid Carcinomas. Thyroid. 2019. PMID: 31407636. doi:10.1089/thy.2019.0065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。